Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D-serine Monotherapy for Treatment Refractory Schizophrenia
NCT00816894Phase 2Completed
- Sponsor
- Herzog Hospital
- Start
- Jan 2009
- Primary completion
- Feb 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of d-serine in schizophrenia and schizoaffective disorder, sponsored by Herzog Hospital. Primary endpoint: Positive and Negative Syndrome Scale at 10 weeks. Started Jan 2009; status: completed.
02
Drugs
d-serine
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT00816894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00816894.